Kuehn Law Encourages LABP, WRK, KAMN and TGAN Investors to Contact Law Firm
NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process:
- Landos Biopharma, Inc. (NASDAQ: LABP) click to participate
AbbVie Inc. will acquire Landos for $20.42 per share in cash, and each share will come with a non-tradable contingent value right per share up to $11.14 in value, contingent upon reaching a clinical development milestone.
- WestRock Company (NYSE: WRK) click to participate
WestRock Company has agreed to be acquired by Smurfit Kappa Group for one new Smurfit WestRock share and $5.00 in cash for each share of WestRock common stock. Under the agreement, WestRock stockholders will receive approximately 49.6% of the combined entity.
- Kaman Corp. (NYSE: KAMN) click to participate
Kaman Corp. is being acquired by Arcline Investment Management, L.P. The agreement stipulates that shareholders of Kaman will receive $46.00 per share in cash upon the completion of the merger.
- Transphorm, Inc. (Nasdaq: TGAN) click to participate
Transphorm has agreed to be acquired by Renesas Electronics. In accordance with the terms of the merger agreement, shareholders of Transphorm will receive $5.10 in cash for each share of Transphorm common stock they own.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
How to Get Involved:
Kuehn Law is dedicated to safeguarding shareholder interests. Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at justin@kuehn.law or call (833) 672-0814. Kuehn Law covers all case costs and does not charge its investor clients. Shareholders are advised to act promptly, as legal rights may be time-sensitive. For additional information, please visit Merger Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track